Global RNAi Technologies Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global RNAi Technologies Market Research Report 2024
RNAi (Ribonucleic Acid Interference) a system in live cells to keep a check on the active genes is the next promising technology in the field of biotechnology. The major classes of RNAi are micro RNA and small interfering RNA. RNAi is said to be the replacement technology for the existing recombinant technology in the field of drug discovery and therapeutics.
According to MRAResearch’s new survey, global RNAi Technologies market is projected to reach US$ 430.3 million in 2033, increasing from US$ 301.3 million in 2022, with the CAGR of 4.8% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole RNAi Technologies market research.
Key companies engaged in the RNAi Technologies industry include Alnylam Pharmaceuticals, Benitec Biopharma Ltd, Filmtec Corporation, Ionis Pharmaceuticals, Quark Pharmaceuticals Inc., RXI Pharmaceuticals, Qiagen, Invitrogen and Ambion, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of RNAi Technologies were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole RNAi Technologies market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global RNAi Technologies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Alnylam Pharmaceuticals
Benitec Biopharma Ltd
Filmtec Corporation
Ionis Pharmaceuticals
Quark Pharmaceuticals Inc.
RXI Pharmaceuticals
Qiagen
Invitrogen
Ambion
Segment by Type
Oncology
Ocular Disorders
Respiratory Disorders
Liver Diseases
Other
Research
Therapeutics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The RNAi Technologies report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global RNAi Technologies market is projected to reach US$ 430.3 million in 2033, increasing from US$ 301.3 million in 2022, with the CAGR of 4.8% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole RNAi Technologies market research.
Key companies engaged in the RNAi Technologies industry include Alnylam Pharmaceuticals, Benitec Biopharma Ltd, Filmtec Corporation, Ionis Pharmaceuticals, Quark Pharmaceuticals Inc., RXI Pharmaceuticals, Qiagen, Invitrogen and Ambion, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of RNAi Technologies were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole RNAi Technologies market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global RNAi Technologies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Alnylam Pharmaceuticals
Benitec Biopharma Ltd
Filmtec Corporation
Ionis Pharmaceuticals
Quark Pharmaceuticals Inc.
RXI Pharmaceuticals
Qiagen
Invitrogen
Ambion
Segment by Type
Oncology
Ocular Disorders
Respiratory Disorders
Liver Diseases
Other
Segment by Application
Research
Therapeutics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The RNAi Technologies report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source